Disease · MONDO_0006019

yaws

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. yaws. Diseases, record MONDO_0006019. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006019

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: yaws; Open Targets
Open Targets ID: MONDO_0006019; Open Targets
Other names: Bouba, Treponema pallidum subsp. pertenue caused disease or disorder, Treponema pallidum subsp. pertenue disease or disorder, Treponema pallidum subsp. pertenue infectious disease, frambesia, frambesia tropica, frambosie, polypapilloma tropicum, thymosis; Open Targets
Disease Ontology: DOID:10371; Disease Ontology
MeSH: D015001; MeSH
NCI Thesaurus: C41353; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 6 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
ALBENDAZOLE	CHEMBL1483	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DIETHYLCARBAMAZINE	CHEMBL684	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
IVERMECTIN	CHEMBL6067487		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LINEZOLID	CHEMBL126	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PENICILLIN G BENZATHINE	CHEMBL3989515	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02344628	Comparison of Two Different Doses of Azithromycin for Treatment of Yaws	Phase 3	583	2018-10-03	Yaws	AZITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT03676140	Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )	Phase 3	20,000		Trachoma, Yaws, Lymphatic Filariases, Scabies, Strongyloidiasis	ALBENDAZOLE, AZITHROMYCIN, DIETHYLCARBAMAZINE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT01955252	Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea	Phase 3	16,000		Yaws	AZITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT05764876	Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)	Phase 3	383		Yaws, Cutaneous Ulcer	AZITHROMYCIN, LINEZOLID	Its record names the disease	ClinicalTrials.gov
NCT01382004	Single-dose Azithromycin for the Treatment of Yaws	Phase 3	255		Yaws, Treponema Infection, Neglected Tropical Disease	AZITHROMYCIN, PENICILLIN G BENZATHINE	Its record names the disease	ClinicalTrials.gov
NCT03664063	PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )	Phase 2	42		Lymphatic Filariasis, Yaws, Trauma	ALBENDAZOLE, AZITHROMYCIN, DIETHYLCARBAMAZINE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AZT30 vs AZT20: Number of Participants With Adverse Events	12 of 291	14 of 292	583	NCT02344628	Trial comparisons
AZT30 vs AZT20: serious adverse events	0 of 291	0 of 292	583	NCT02344628	Trial comparisons
AZT30 vs AZT20: Number of Participants With Clinical and Serological Cure in Latent Yaws	65 of 125	73 of 124	249	NCT02344628	Trial comparisons
AZT30 vs AZT20: Number of Participants With Clinical and Serological Cure	68 of 81	61 of 76	157	NCT02344628	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42848323	DERIVED	1	PubMed
37262040	DERIVED	1	PubMed
32818264	DERIVED	1	PubMed
29456191	DERIVED	1	PubMed
29428183	DERIVED	1	PubMed
29107621	DERIVED	1	PubMed
25693010	DERIVED	1	PubMed
22240407	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006019

GET https://conductscience.org/api/diseases/v1/MONDO_0006019/drugs

API reference For AI assistants